The UK’s BioIndustry Association (BIA) has published research suggesting that the country’s medicines evaluation body is basing its methods and processes for ev 6 April 2023
The National Institute for Health and Care Excellence (NICE) has recommended the provision of Lynparza (olaparib) for National Health Service (NHS) patients wit 6 April 2023
The administrators of the USA’s public insurance scheme, Medicare, are getting ready to implement the measures included in the Inflation Reduction Act. 4 April 2023
Improving the availability of innovative medicines in Latin America is a key priority for the pharmaceutical industry, policymakers, and patients. 31 March 2023
US biopharma PTC Therapeutics has come to an agreement with National Health Service (NHS) England for the reimbursement of its rare disease drug Upstaza (eladoc 24 March 2023
Drugmakers have welcomed the European Commission’s commitment to a “competitiveness check,” related to the legislative environment in the region. 21 March 2023
Patient advocacy groups have expressed regret at Janssen’s decision to hit the pause button on its UK launch of Carvykti (ciltacabtagene autoleucel). 20 March 2023
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.